AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NTLA · NASDAQ · Biotechnology

Intellia Therapeutics (NTLA)

Develops CRISPR medicines led by lonvo-z and nex-z.

$12.09

vs last close−0.60 (−4.73%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	12	−2	29	7	9	13	17	14	14	23	15	8
Cost of revenue	2	2	3	3	109	117	0	81	79	6	2	0
Gross profit	10	−4	26	4	−100	−104	17	−66	−65	17	13	8
	141	136	140	143	45	32	137	44	46	116	113	120
Research & development	114	109	109	112	123	117	108	97	95	89	81	83
	29	29	31	32	45	32	29	44	46	33	35	38
Selling & marketing	0	0	0	0	14	0	0	17	16	0	0	0
General & administrative	29	29	31	32	31	32	29	27	31	33	35	38
Other expenses	−2	−2	0	0	−123	−117	0	−97	−95	−6	−2	0
Operating income	−131	−140	−114	−139	−145	−136	−121	−110	−111	−99	−101	−113
	9	8	7	−8	9	8	6	9	10	3	4	6
Interest income	13	12	13	12	12	11	9	7	7	6	5	6
Other non-operating income	0	−8	−7	8	−9	−8	−6	−9	−10	−3	−4	−6
Income before tax	−122	−132	−107	−147	−136	−129	−114	−101	−101	−96	−96	−107
Net income from continuing operations	−122	−132	−107	−147	−136	−129	−114	−101	−101	−96	−96	−107
Net income	−122	−132	−107	−147	−136	−129	−114	−101	−101	−96	−96	−107
EPS, basic	−$1.38	−$1.46	−$1.12	−$1.52	−$1.34	−$1.27	−$1.10	−$0.98	−$0.92	−$0.83	−$0.81	−$0.80
EPS, diluted	−$1.38	−$1.46	−$1.12	−$1.52	−$1.34	−$1.27	−$1.10	−$0.98	−$0.92	−$0.83	−$0.81	−$0.80
Weighted average shares, basic	89	90	96	97	101	102	104	104	110	108	118	133
Weighted average shares, diluted	89	90	96	97	101	102	104	104	110	108	118	133
EBITDA	−129	−130	−105	−144	−133	−126	−112	−99	−96	−95	−94	−105
Depreciation & amortization	2	2	3	3	3	3	2	2	5	0	2	2
EBIT	−131	−132	−107	−147	−136	−129	−114	−101	−101	−96	−96	−107